Well, as Dr. Hidalgo, Principal Investigator of PharmaCyte’s trial, says, “If the results are positive, these results may pave the way for an accelerated approval process through one or more avenues afforded by the FDA.”
Timing is always important especially when dealing with the stock market. What may be more crucial is when we’re talking about the biotech sector. Whether it’s phase trials or things like an investigational new drug designation, events like this could act and have acted as serious catalysts for countless companies.
Here’s why an open IND is key to PMCB realizing a number of benefits that include:
Beginning the formal arrangements required to conduct its clinical trial in LAPC.
Working towards the major milestone of enrolling the first patient in its clinical trial.
Publishing that the technology behind its LAPC treatment has passed the incredibly difficult FDA screening process and met all of the FDA’s regulatory requirements.
Building global exposure of PharmaCyte’s Cell-in-a-Box® technology.
Paving the way for the development of treatments for multiple diseases including diabetes and a host of solid tumors.
But aside from this, timing is so important right now because an approved IND submission would mean clinical trials could begin 30 calendar days from the submission date of the IND!
The best part: the data obtained to date from the encapsulation parameters of the manufacturing process itself indicate that the encapsulation portion of the process is fault free and reproducible, which is a fundamental requirement of the FDA.
Could those looking at PMCB at this exact moment be looking at a right place/right time scenario?
Do you understand how big of an addressable market this could be for PharmaCyte?
Cancer drug sales are on track to eclipse the $200 billion mark early in the next decade [3], thanks to an innovation bonanza that’s transformed oncology into the fastest-growing segment across the entire pharmaceutical industry.
Specifically, a recent report [4] by EvaluatePharma estimated that global cancer drug sales could rise at a blistering compound annual growth rate of 12% over the next five years. When you talk about timing, this could be that moment in time to be actively looking for “the curve” and how to be ahead of it before the sector realizes such immense growth!
Cancer-Fighting Stocks Are Getting Bought Before Investors Can Get Their Hands On Them
The global market for cancer drugs is huge and big players are investing heavily to gain an edge in this increasingly competitive market. In many cases, the average investor hasn’t had a chance to look at game-changing biotech companies lately for the simple reason that pharmaceutical giants are hot on the acquisition trail.
Bristol-Myers, a pioneer in immunotherapy, acquired rival Celgene for $74 billion. On top of this, Merck acquired cancer drug developer Peloton Therapeutics for $1.05 billion. The announcement came at the same time that Peloton was preparing for its IPO!
This isn’t “just another cancer company.” PMCB has developed a technology that could completely change the way cell therapies are conducted! Right now, the company isn’t just focused on cancer, they’ve also begun to apply Cell In A Box ® to other diseases like Diabetes.
AI
